CoreSite Realty

CoreSite Realty

Yahoo Finance • 6 hours ago

Cencora’s (NYSE:COR) Q3 CY2026 earnings results: revenue in line with expectations

Cencora's (NYSE:COR) Q3 CY2026 earnings results: revenue in line with expectations Healthcare distributor Cencora (NYSE:COR) met Wall Street's revenue expectations in calendar Q3 2026 (fiscal Q4 2026), with revenue up 5.5% year on year to... Full story

Yahoo Finance • 6 hours ago

Cencora: Fiscal Q4 Earnings Snapshot

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal fourth-quarter earnings of $519.4 million. The Conshohocken, Pennsylvania-based company said it had net income of $2.71 per share. Earnings... Full story

Yahoo Finance • 6 hours ago

Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus

CONSHOHOCKEN, Pa., November 04, 2026--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. "Over the last two years, Cencora has tak... Full story

Yahoo Finance • 6 hours ago

Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results

Fourth Quarter Revenue of $88.4 Billion up 5.5 Percent. GAAP Diluted EPS of $2.71 and Adjusted Diluted EPS of $4.66 Fiscal Year 2026 Revenue of $337.4 Billion up 5.0 Percent. GAAP Diluted EPS of $17.95 and Adjusted Diluted EPS of $17.97... Full story

Yahoo Finance • 4 days ago

What Does Cencora (COR) Gain From Expanding Into 12 More States?

Cencora (NYSE: COR) agreed to acquire American Oncology Network to expand its community-based cancer care footprint. The deal broadens Cencora's physician practice management services into 12 additional states through American Oncology Net... Full story

Yahoo Finance • 11 days ago

Key deals this week: Visa, London Stock Exchange, Tradeweb Markets, Salesforce, and more

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Here's a list of key deals reported across sectors this week: Visa Inc. (V [https://seekingalpha.com/symbol/V]) is said to be in advanced discussions... Full story

Yahoo Finance • 19 days ago

Cencora (COR): 3 Reasons We Love This Stock

Cencora (COR): 3 Reasons We Love This Stock Cencora has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to $341.69 per share while the index has gained 9.7%... Full story

Yahoo Finance • last month

Camino Receives Environmental Approval for Significant Exploration Expansion at the Costa de Cobre Copper Project in Peru

Approval Nearly Doubles Exploration Footprint and Adds 212,500 Metres of Potential Drilling CapacityAcross Three Major Copper Trends VANCOUVER, BC / ACCESS Newswire / September 28, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF... Full story

Yahoo Finance • last month

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa., September 25, 2026--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Execu... Full story

Yahoo Finance • last month

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Key Points Interested in Cencora, Inc.? Here are five stocks we like better. Specialty pharmaceuticals and MSOs are central to Cencora's growth strategy, with particular emphasis on retina and oncology practices. Management expects the MS... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: Novo Nordisk, GE HealthCare, and Eli Lilly in focus

Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating macroeconomic backdrop. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-n... Full story

Yahoo Finance • 2 months ago

Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?

On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and mana... Full story

Yahoo Finance • 2 months ago

Cencora Tech Chief: AI Is Cutting Some Medical Treatment Decisions in Half

Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma des... Full story

Yahoo Finance • 2 months ago

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is... Full story

Yahoo Finance • 2 months ago

Coultreon Biopharma Appoints Nate Massari as Chief Business Officer

Coultreon Biopharma BV Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn's disease, will support the advancement of Coultreon's first-in-cl... Full story

Yahoo Finance • 2 months ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • 2 months ago

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d... Full story

Yahoo Finance • 2 months ago

2 S&P 500 Stocks with Exciting Potential and 1 We Question

2 S&P 500 Stocks with Exciting Potential and 1 We Question The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are c... Full story

Yahoo Finance • 2 months ago

Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Should you bet on an established giant or a pipeline-driven innovator? This comparison examines Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) to see which stock is a better buy today. Amgen is a veteran in the drug manufacturing world, fo... Full story

Yahoo Finance • 2 months ago

Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

Cencora COR raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks... Full story